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Abstract
Background:  We examined whether quarterly patient enrollment in a large multicenter clinical
trials group could be modeled in terms of predictors including time parameters (such as long-term
trends and seasonality), the effect of large trials and the number of new studies launched each
quarter. We used the database of all clinical studies launched by the AIDS Clinical Trials Group
(ACTG) between October 1986 and November 1999. Analyses were performed in two datasets:
one included all studies and substudies (n = 475, total enrollment 69,992 patients) and the other
included only main studies (n = 352, total enrollment 57,563 patients).
Results:  Enrollment differed across different months of the year with peaks in spring and late fall.
Enrollment accelerated over time (+27 patients per quarter for all studies and +16 patients per
quarter for the main studies, p < 0.001) and was affected by the performance of large studies with
target sample size > 1,000 (p < 0.001). These relationships remained significant in multivariate
autoregressive modeling. A time series based on enrollment during the first 32 quarters could
forecast adequately the remaining 21 quarters.
Conclusions:  The fate and popularity of large trials may determine the overall recruitment of
multicenter groups. Modeling of enrollment rates may be used to comprehend long-term patterns
and to perform future strategic planning.
Background
Adequate patient recruitment is an important prerequi-
site for the optimal function of multicenter clinical trials
groups. Such groups are likely to perform several clinical
trials concurrently across a number of participating clin-
ical sites. The number of patients enrolled over time may
thus depend on the capabilities of the participating cent-
ers as well as on the type and sample size of studies that
are open at a given time. The enrollment performance of
a clinical trials group may also change gradually over
time. It would be useful if one could predict enrollment
in the future based on past trends and on the new trials
that are launched or being proposed. This knowledge
may offer useful insight for future strategic planning. In
particular, large trials may pose an especially higher bur-
den on the group in terms of patient recruitment. Addi-
tionally, there are anecdotal beliefs that patient
enrollment may show seasonal variability with fewer pa-
tients enrolled in the summer months or during the win-
ter holidays season, when enrollment efforts may be
diminished. However, there are no good empirical data
addressing these issues.
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In the present study we evaluated whether we could
identify predictors of the overall rate of enrollment in a
large multicenter clinical trials group that has been con-
ducting clinical studies in the domain of human immun-
odeficiency virus (HIV) infection for over 13 years.
Detailed data were available on enrollment (on-study
dates) on nearly 70,000 patient entries from 475 studies.
This offered the opportunity for examining the effect of
long-term trends, new studies, large studies and season-
al parameters on the enrollment and for evaluating
whether future enrollment can be forecast based on past
performance.
Material and Methods
Databases
We used data from the AIDS (acquired immunodeficien-
cy syndrome) Clinical Trials Group (ACTG) on the accru-
al of patients in clinical studies between October 10, 1986
and November 12, 1996. All ACTG clinical studies were
considered, including both randomized and non-rand-
omized designs of all phases (I-IV). ACTG is sponsored
by the Division of AIDS of the National Institute of Aller-
gy and Infectious Diseases (NIAID) and it represents a
large network for the conduct of clinical studies on HIV
infection and its complications. ACTG performs studies
both in adults (Adult ACTG) and in children (Pediatric
ACTG). It uses the clinical resources of the network of 30
university sites and many other affiliated centers across
the United States. The performance of sites is evaluated
regularly and re-competition occurs approximately every
4 years; at some re-competition cycles a few sites have
been replaced by new ones, however the total number of
sites has remained relatively constant.
On-study dates were used for all the analyses. All analy-
ses were performed in two datasets: one considered all
ACTG studies and the other one excluded the recruit-
ment in substudies of main studies. The analyses exclud-
ing substudies may be more robust, because by
definition substudies typically included only subsets of
the same patients as the main studies. For occasional
studies, the ACTG had collaborated with other multi-
center organizations, such as the Community Programs
for Clinical Research on AIDS. In these cases, typically
only data on the ACTG-site patients were available in the
dataset.
Seasonal effect: patient enrollment and initiation of stud-
ies
First, we examined using the chi-square test whether
there is a seasonal effect affecting patient recruitment
and the initiation of new studies. Histograms summa-
rized the number of patients enrolled every month and
the number of studies starting every month of the year
from the start of 1987 through the end of 1998.
Candidate predictors of enrollment
We evaluated whether the total ACTG enrollment may be
influenced by the following parameters:
1. Trend over time - examination of the raw data suggest-
ed that a linear trend with increasing quarterly enroll-
ment over time may be present. Alternative
transformations (such as logarithmic) were also probed,
but the fit was not improved.
2. Early "starting" effect - it is anticipated that the overall
enrollment of a multicenter clinical trials group may
need some time to reach a functional level when the
group is first established, since sites may not register at
the same time and some time is needed for a critical
number of studies to be launched. Examination of the
raw data suggested that this early effect might be mod-
eled by the introduction of an indicator variable for the
first 3 quarters (9 months).
3. Seasonal effect - dummy variables were employed
where the reference season was winter.
4. The effect of launching large studies - large studies
may boost the overall enrollment of a clinical trials group
due to their excessive demands on patient recruitment.
The definition of what consists a large study is arbitrary.
We considered a priori all ACTG studies with target en-
rollment exceeding 1,000 patients where a prevalent eli-
gible patient pool is already available for enrollment
when a study is launched. We generally excluded pro-
spective studies of HIV perinatal transmission (the prev-
alent pool of HIV-infected pregnant women is small).
The effect of large trials was modeled by giving weights
for extra enrollment in the early quarters of their accrual.
Specifically, for studies with target sample size over
1,000 patients, the weight was 1/2 for the quarter during
which they were initiated, 1 for the subsequent quarter,
and 1/2 for the next quarter. For parsimony, the "active"
effects of large studies were considered to be negligible
beyond the third quarter. These weights were used em-
pirically, because the raw data suggested that, although
exceptions may occur, on average large studies tend to
have their peak accrual at the second quarter from their
onset [1]. The overall effect of large studies was con-
structed by summing up the respective weights of the
large studies that were "active" in each quarter. In a sen-
sitivity analysis, studies with target sample size between
500 and 1,000 patients were also considered using half
the weights described above, but the fit was not im-
proved (not shown).
5. Number of studies starting each quarter - the vast ma-
jority of studies launched by the ACTG have fewer than
1,000 (or 500) patients. For such studies, the typical en-BMC Medical Research Methodology (2001) 1:4 http://www.biomedcentral.com/1471-2288/1/4
rollment period is short (most often less than half a year
or even just a few months). To model this effect, we con-
sidered as a predictor the number of studies starting in
each quarter. Sensitivity analysis, considering also as a
predictor the number of studies starting in the preceding
quarter, did not improve the model fit (not shown). For
parsimony, we only consider the current quarter variable
in the presented analyses.
Time series modeling
Evaluation of correlograms on the raw data and after the
time trend had been removed, suggested that a first-or-
der autoregressive model may be appropriate, since
there was a high first lag autocorrelation coefficient and
exponentially tapering, non-significant higher-lag auto-
correlation coefficients, while the partial autocorrelation
function showed only one prominent term at lag one.
Therefore, we also examined the effect of the linear time
trend in a first-order autoregressive model [2]. Further-
more, we also adjusted this model separately for season-
al effect, early "starting" effect, the effect of large studies
and the number of new studies starting each quarter in
order to see whether the significance and magnitude of
the autoregressive effect was altered once these parame-
ters were taken into account. Finally, a multivariate
model was considered, employing all the predictors
above as well as a first-order autoregressive term.
Training and forecasting
Using a first-order autoregressive multivariate model
with the same parameters, another training model based
on the enrollment of the first 32 quarters was used to
forecast the enrollment of the remaining 21 quarters. For
all the above time series analyses sequence graphs with
predicted and observed quarterly enrollment were visu-
alized and both the absolute and proportional differenc-
es were calculated.
Statistical analyses were conducted in SPSS version 9.0
(SPSS Inc, Chicago, IL). All reported p-values are two-
tailed.
Results
Between October 1986 and November 1999, 475 ACTG
studies were launched with a total enrollment of 69,992
patients. Excluding substudies, there were 352 main
studies with a total enrollment of 57,563 patients. When
limited to the period January 1, 1987 to December 31,
1998, there were a total of 441 studies (62,995 patients),
including a total of 334 main studies (51,927 patients).
Enrollment differed significantly between different
months, (p < 0.001, figures 1 and 2). Patient recruitment
peaked in spring (March, April) and late fall (October,
November) while it was slower during the winter months
and in September. Despite a trend for an increased
number of studies starting in October and May, overall
the number of studies starting each month did not differ
significantly (p = 0.060 for all ACTG studies, p = 0.359
excluding substudies).
In univariate regressions (table 1), recruitment acceler-
ated over time; on average the acceleration per quarter
was approximately 27 patients when all studies were
considered (p < 0.001) and 16 patients when substudies
were excluded (p < 0.001). Also the effect of large rand-
omized trials contributed significantly to patient enroll-
ment (p < 0.001). Compared to the early enrollment
during the first three quarters, more patients were re-
cruited later on (p < 0.001 for all ACTG studies and p =
0.001 for main studies, respectively). The number of
studies and substudies starting each quarter seemed to
influence enrollment (p = 0.001) when all ACTG studies
were considered, but this was not true when the substud-
ies were excluded (p = 0.97). More patients seemed to be
accrued during spring, but the seasonal effect was overall
not very prominent.
We evaluated also models taking autocorrelation into ac-
count. The effect of the time trend was similar (27.78 per
quarter [p < 0.001] and 16.72 per quarter [p < 0.001]
when all ACTG studies or all studies excluding substud-
ies were considered, respectively) when a first-order au-
toregression term (AR1) was added (coefficient for AR1
0.38, [p = 0.005] and 0.27, [p = 0.048], respectively).
The AR1 coefficient remained largely unaltered when ad-
justment was made also for season (0.40, [p = 0.004]
and 0.29, [p = 0.041], respectively) or for the three early
starting quarters in the dataset of all ACTG studies (0.35,
[p = 0.011]; AR1 coefficient 0.18, [p = 0.208], in the da-
taset excluding substudies) or the number of studies
starting each quarter (0.44, [p < 0.001] and 0.27, [p =
0.052], respectively). On the contrary, the AR1 coeffi-
cient was substantially attenuated and was no longer sig-
nificant when the effect of large studies was considered
(0.24, [p = 0.082] and 0.20, [p = 0.159], respectively).
In multivariate modeling with first-order autocorrela-
tion being considered, the time trend and large trials
seemed to be the most important determinants of the
quarterly enrollment (table 1). The autoregressive term
was not important. The fit for all ACTG studies and ex-
cluding substudies is presented in figures 3 and 4.
When the training model based on the first 32 quarters
was assessed (table 2), the coefficients were largely sim-
ilar to the final multivariate model described above. In
figures 5 and 6. the fit of this training model is presented
including its ability to forecast the enrollment during the
subsequent 21 quarters. Considering the sequence graphBMC Medical Research Methodology (2001) 1:4 http://www.biomedcentral.com/1471-2288/1/4
based on all ACTG studies, the difference between ob-
served and predicted exceeded 400 patient entries in 6
forecast quarters and the mean absolute difference was
346. The maximal absolute difference between observed
and predicted enrollment in forecast quarters was 856
patients. When all studies were considered, the predic-
tion missed the actual observed accrual by over 30% in 5
quarters and the average relative deviation from the ob-
served accrual was 24.7%. At the largest deviation, the
predicted deviation was double than the observed accru-
al. When the substudies were excluded, the forecast was
even better. The maximal absolute difference between
observed and predicted enrollment in forecast quarters
was 723 patients, the absolute difference was more than
400 patients in only 5 forecast quarters and the mean ab-
solute difference was 249. Excluding substudies, the pre-
diction also missed the actual observed accrual by over
30% in 5 quarters and the average relative deviation
from the observed accrual was 20.8%. At the largest de-
viation, the predicted accrual was 69% larger than the
observed accrual. For both predictions, the largest diver-
gence from the observed enrollment was seen in the pe-
riod between summer 1996 and winter 1996-1997.
Discussion
The performance of large studies with target sample size
above 1,000 patients is a key determinant of the overall
number of patients recruited by a multicenter clinical tri-
als group. Also, there was strong evidence in the ACTG of
an increase in enrollment performance over time. Al-
Figure 1
Overall enrollment per month of the year for all ACTG studies (1987-1998)BMC Medical Research Methodology (2001) 1:4 http://www.biomedcentral.com/1471-2288/1/4
though the acceleration over time was significantly relat-
ed to an increasing number of studies (particularly
substudies) being launched over time, the dynamics of
the acceleration of enrollment were more complex. The
long-term time trend may reflect an increasing efficiency
of the group and better networking for the referral of pa-
tients for participation into clinical trial initiatives. Other
candidate predictors were less prominent. We identified
a clear monthly variation with peaks in October-Novem-
ber and springtime and with troughs in summer and
winter, mostly for patient enrollment than for the initia-
tion of new studies. However, this variation did not
translate to a strong seasonal effect. For example, Sep-
tember had the lowest enrollment of all months of the
year, thus attenuating whatever typical seasonal pattern
might exist.
The data suggested the presence of a strong first-order
autoregressive parameter. This is not surprising, since
enrollment in a given quarter is likely to be influenced by
what the level of enrollment had been in the previous
quarter. Intuitively, this may reflect the ongoing trial ac-
tivity in the multicenter clinical trials group, and large
studies may be the most important component of this ac-
tivity in this regard. Thus, the magnitude of the autore-
gressive term was markedly diminished when the effect
of large trials was taken into account, while it remained
unaltered when other candidate predictors were consid-
ered.
The forecasting ability of a training model based on the
first 32 quarters was satisfactory. Enrollment was fore-
cast adequately for a period exceeding 5 years, which
represents a very long period of time, far longer than an-
Figure 2
Overall enrollment per month of the year for all ACTG studies excluding substudies (1987-1998).BMC Medical Research Methodology (2001) 1:4 http://www.biomedcentral.com/1471-2288/1/4
ything that might be needed for planning purposes. In-
terestingly, forecasting was most inadequate between
the summer of 1996 and the winter of 1996-1997 when
the model predicted good overall enrollment, while a rel-
atively deep trough was observed in reality. This may be
explained, because in the summer of 1996, ACTG 320, a
large trial with target enrollment of 1,750 patients, expe-
rienced a sharp, unexpected decline in its rate of enroll-
ment despite an early rigorous accrual pattern. The study
fell short of its target accrual (final sample size n = 1,178).
Early interim analyses showed a large treatment differ-
ence and led to early termination (January 1997) [3].
Based on early surrogate marker trials that suggested the
superiority of triple drug regimens, the study had came
under attack in the summer of 1996 from various advo-
cacy groups. The crisis escalated in the fall and winter.
Perhaps this crisis may have affected accrual also in oth-
er ACTG trials at that time. Although ACTG 320 is a spe-
cial case, this example further shows the importance that
large trials may have for the materialization of the overall
program of a group of clinical investigators. Some large
trials may become reference points for a group, and their
fate may influence the course of the group as a whole. A
far more dramatic example is available from the breast
cancer literature [4], where allegations to the falsifica-
tion of some limited trial data led to a large trough in the
enrollment of a very experienced group of trialists.
Although we deem that the overall predictive perform-
ance of the developed models was satisfactory, of course
we should acknowledge that the adequacy of the fore-
casting ability depends also on a subjective interpreta-
tion of the results. Under different settings, it may be
necessary to achieve even tighter predictions for the per-
Figure 3
Observed and predicted number of patients enrolled every quarter in ACTG studies during October 1986-November 1999.BMC Medical Research Methodology (2001) 1:4 http://www.biomedcentral.com/1471-2288/1/4
formance of a model to be satisfactory for operational
use by a multicenter clinical trials group.
Previous research that has been conducted to describe
patient recruitment in various areas has mainly focused
on the study protocols or the institutional sites
[5,6,7,8,9,10,11,12]. There has been debate on whether
simple enrollment should be considered as a key deter-
minant of site performance [5,6,10]. Besides enrollment,
data quality and patient retention obviously need to be
considered as well [5,13]. Moreover, different studies en-
tail different levels of effort per patient enrolled. While
some studies require simple follow-up, others may be far
more labor-and data-intensive and may demand special-
ized expertise. Simple enrollment rates cannot convey
this complex information neither for specific sites nor for
a clinical trials group as a whole. Nevertheless, overall
enrollment rates may still be a useful piece of informa-
tion in trying to assess group performance over time. Our
analysis has focused on this perspective and has shown
that there are identifiable factors affecting the overall pa-
tient enrollment and that predicted enrollment is fairly
sensitive to these simple predictors. This information
may be used in monitoring the progress of a group and in
planning ahead the strategic development and the incor-
poration of future trials in its program. Coupled with
data on anticipated cost [14,15] and intensity of data col-
lection and analysis, the forecasts on enrollment may im-
prove rational group steering.
Some of the limitations of our study include the relatively
arbitrary definition of large trials [16,17] and the fact that
Figure 4
Observed and predicted number of patients enrolled every quarter in all ACTG studies excluding substudies during October
1986 - November 1999.BMC Medical Research Methodology (2001) 1:4 http://www.biomedcentral.com/1471-2288/1/4
our analysis pertains to a specific group of clinical inves-
tigators with activities restricted to the field of HIV infec-
tion. Regarding the large study definition, it was
unavoidable that an a priori approach had to be decided
upon. The cut-off of 1,000 patients has been used also in
previous methodologic research [16,17]. Nevertheless,
results were robust also when studies with a target sam-
ple size more than 500 subjects was considered. It is con-
ceivable that the definition of a large study may differ in
different fields. No mega-trials with over 10,000 patients
have yet been performed in the field of HIV infection and
the largest ACTG trial has had slightly over 3,000 pa-
tients. For groups performing large studies with a wide
range of sample sizes (including mega-trials), the
weighting scheme for modeling the effect of large trials
may need to show more gradation, based on the target
sample size.
Finally, even though our analysis refers to a particular
clinical trials group, the predictors and the modeling
process may be generalized to other groups and settings.
Comparative analyses in other groups may evaluate
whether some of the predictors considered here, such as
the seasonal effect, may differ between various medical
fields. For example, seasonal effects are likely to be far
more prominent for diseases that show seasonality in
their incidence. On the other hand, other predictors,
such as the effect of large trials, may be consistently im-
portant across diverse settings.
Figure 5
Observed and predicted number of patients enrolled every quarter in all ACTG studies during October 1986-November 1999.
The model was trained on the first 32 quarters and forecasting was performed for the remaining 21 quarters.BMC Medical Research Methodology (2001) 1:4 http://www.biomedcentral.com/1471-2288/1/4
Figure 6
Observed and predicted number of patients enrolled every quarter in all ACTG studies excluding substudies during October
1986 - November 1999. The model was trained on the first 32 quarters and forecasting was performed for the remaining 21
quarters.BMC Medical Research Methodology (2001) 1:4 http://www.biomedcentral.com/1471-2288/1/4
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Table 1: Simple regression and multivariate first-order autoregressive models on the number of patients enrolled every quarter.
All ACTG studies Excluding substudies
Univariate Multivariate* Univariate Multivariate
Parameters Effect (95% CI) Effect (95% CI) Effect (95% CI) Effect (95% CI)
Time trend effect (per 
quarter)
27.1 (18.9, 35.4) ¶ 24.5 (17.6, 31.5) ¶ 16.1(10.1, 22.1) ¶ 14.7 (9.4, 20.2) ¶
Large studies effect ‡ (per point 
weight)
607.9 (284.5, 931.4) ¶ 701.0 (507.7, 894.4) ¶ 403.0 (185.6, 20.3) ¶ 415.1 (261.0, 569.3) ¶
Early starting effect § -1196.0 (-1858.4,-
533.7) ¶
-141.6 (-577.6, 294.3) -947.4 (-1367.8, -527.0) ¶ -429.2 (-786.9, -47.9) #
Studies starting in same quarter (per 
study)
59.6 (25.2, 94.0) ¶ 31.2 (10.6, 51.8) # 0.7 (-35.9,37.2) 1.6 (-22.0,25.3)
Seasonal effect
Spring 277.7 (-267.4, 722.8) 126.3 (-89.5, 342.1) 166.9 (-164.4, 498.1) 147.7 (-44.2, 339.5)
Summer 136.9 (-358.3, 632.0) 115.5 (-110.4, 341.3) 75.5 (-255.7, 406.7) 41.9 (-150.2, 233.9)
Fall 31.0 (-455.2, 517.2) 27.8 (-181.7, 237.2) 21.4 (-303.9, 346.6) 41.8 (-141.5, 225.1)
AR1 0.15 (-0.14, 0.45) 0.06  (-0.24, 0.35)
ACTG: AIDS Clinical Trials Group, CI: confidence interval AR1: first-order autoregressive parameter * Constant in model = 109.7 (p = 0.47) † Con-
stant in model = 520.3 (p < 0.001) ‡ Sum of weights for large studies in each quarter: 1/2 for a large study which is initiated in that quarter, 1 for a 
large study which is on its second quarter of enrollment, and 1/2 for a large study which is on its third quarter of enrollment. §Dummy variable for 
first 3 quarters (Fall 1986-Spring 1987) ¶ p < 0.001 # 0.001 ≤  p < 0.05
Table 2: Training model based on the first 32 quarters of enrollment
All ACTG studies Excluding substudies
Parameters Effect (95% CI) Effect (95% CI)
AR1 0.04 (-0.37, 0.46) -0.09 (-0.51, 0.33)
Time trend effect 29.7 (18.9, 40.5) ‡ 12.8 (3.9, 21.7) §
(per quarter)
Large studies effect *(per point weight) 699.7 (535.5, 864.0) ‡ 420.3 (284.2, 556.4) ‡
Early starting effect † -83.3 (-427.3, 260.7) -436.7 (-731.1,-142.2) §
Studies starting in same quarter (per study) 20.6 (-1.4, 42.5) -1.0 (-23.5, 21.4)
Seasonal effect
Spring 152.7 (-78.8, 406.2) 189.3 (-32.4, 410.9)
Summer 185.3 (-43.2, 413.7) 115.3 (-90.6, 321.2)
Fall -144.5 (-365.2, 76.2) -96.7 (-308.8, 115.4)
Constant 137.5 (-152.2, 427.2) 576.5 (309.3, 843.7) ‡
ACTG: AIDS Clinical Trials Group, AR1: First-order autoregressive parameter * Sum of weights for large studies in each quarter: 1/2 for a large study 
which is initiated in that quarter, 1 for a large study which is on its second quarter of enrollment, and 1/2 for a large study which is on its third quarter 
of enrollment. † Dummy variable for first 3 quarters (Fall 1986-Spring 1987) ‡ p < 0.001 §0.001 ≤  p < 0.05BMC Medical Research Methodology (2001) 1:4 http://www.biomedcentral.com/1471-2288/1/4
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